ArticleNeurology and therapy2026
Treatment Characteristics and Healthcare Resource Utilization Among Patients with Myasthenia Gravis Initiating Rozanolixizumab: A US Claims Database Analysis.
Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRozanolixizumab is indicated for the treatment of adults with generalized myasthenia gravis (MG). This retrospective, non-interventional cohort study evaluated adults with MG initiating rozanolixizumab in the USA.
methodsPatients were selected from de-identified claims data from the Komodo Healthcare Map
resultsThe main study included 719 patients. Patients with ≥ 365 days since rozanolixizumab initiation (n = 287) started a mean (standard deviation) 2.9 (1.8) treatment cycles in Year 1. Total MG-related HCRU incidence rates per 100 person-years were 88.0 during baseline and 82.9 during follow-up, and 86.2 versus 80.8 for outpatient, 25.6 versus 17.3 for inpatient, and 24.9 versus 14.0 for emergency room visits. Approximately half (53.7%, 386/719) of patients used corticosteroids at baseline and had ≥ 3 months' follow-up. 29.0% (n = 112) tapered their dose by ≥ 5 mg, and a further 29.3% (n = 113) discontinued corticosteroids during follow-up. In patients who had ≥ 1 claim for efgartigimod before initiating rozanolixizumab (n = 26), 19.2% tapered corticosteroids by ≥ 5 mg during follow-up, and 7.7% discontinued completely.
conclusionThis real-world study of patients receiving rozanolixizumab in the USA showed reductions in corticosteroid use and HCRU following rozanolixizumab initiation, including in those who switched from efgartigimod. The mean number of rozanolixizumab cycles (2.9) was lower than the mean 4.1 cycles in Phase 3 studies (patients with ≥ 1 year of follow-up), demonstrating that treatment patterns in clinical practice can be individually adjusted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.